Back to top

Editas Medicine Reaches Analyst Target Price

In recent trading, shares of Editas Medicine Inc (EDIT) have crossed above the average analyst 12-month target price of $3.11, changing hands for $3.15/share. When a stock reaches the target an analyst has set, the analyst logically has two ways to react: downgrade on valuation, or, re-adjust their target price to a higher level..

Read full article here »

In-Depth Zacks Research for the Tickers Above

Normally $25 each - click below to receive one report FREE:

Editas Medicine, Inc. (EDIT)